Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

T. S. Larsen*, O. W. Bjerrum, N. Pallisgaard, M. T. Andersen, M. B. Møller, H. C. Hasselbalch

*Corresponding author

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response.

TidsskriftAnnals of Hematology
Udgave nummer10
Sider (fra-til)847-850
Antal sider4
StatusUdgivet - 2008
Udgivet eksterntJa


  • Interferon
  • JAK2
  • PCR
  • Polycythemia vera
  • Remission

Citer dette